CPRX vs. AGIO, EVO, AMPH, KROS, GLPG, SNDX, NAMS, ARDX, DCPH, and AMRX
Should you be buying Catalyst Pharmaceuticals stock or one of its competitors? The main competitors of Catalyst Pharmaceuticals include Agios Pharmaceuticals (AGIO), Evotec (EVO), Amphastar Pharmaceuticals (AMPH), Keros Therapeutics (KROS), Galapagos (GLPG), Syndax Pharmaceuticals (SNDX), NewAmsterdam Pharma (NAMS), Ardelyx (ARDX), Deciphera Pharmaceuticals (DCPH), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical preparations" industry.
Agios Pharmaceuticals (NASDAQ:AGIO) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, community ranking, institutional ownership, analyst recommendations, profitability and media sentiment.
In the previous week, Catalyst Pharmaceuticals had 2 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 5 mentions for Catalyst Pharmaceuticals and 3 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.97 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.
Catalyst Pharmaceuticals has a net margin of 15.83% compared to Catalyst Pharmaceuticals' net margin of -1,199.26%. Agios Pharmaceuticals' return on equity of 25.08% beat Catalyst Pharmaceuticals' return on equity.
Catalyst Pharmaceuticals received 5 more outperform votes than Agios Pharmaceuticals when rated by MarketBeat users. Likewise, 74.31% of users gave Catalyst Pharmaceuticals an outperform vote while only 67.71% of users gave Agios Pharmaceuticals an outperform vote.
Agios Pharmaceuticals has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.
79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 4.9% of Agios Pharmaceuticals shares are held by company insiders. Comparatively, 11.0% of Catalyst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Catalyst Pharmaceuticals has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Agios Pharmaceuticals presently has a consensus target price of $35.00, indicating a potential upside of 1.92%. Catalyst Pharmaceuticals has a consensus target price of $26.71, indicating a potential upside of 60.93%. Given Agios Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Catalyst Pharmaceuticals is more favorable than Agios Pharmaceuticals.
Summary
Catalyst Pharmaceuticals beats Agios Pharmaceuticals on 17 of the 18 factors compared between the two stocks.
Get Catalyst Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Catalyst Pharmaceuticals Competitors List
Related Companies and Tools
